[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370263-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370263-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","full-length-transcriptome-atlas-of-gallbladder-cancer-reveals-trastuzumab-resistance-conferred-by-erbb2-alternative-splicing","Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing","","Gallbladder cancer is an aggressive digestive malignancy often diagnosed late, limiting patients to non-invasive options such as chemotherapy and targeted therapy, while effective targeted strategies remain scarce. Using long-read full-length transcriptome sequencing across normal tissues, tumors, and cell lines, the study builds a gallbladder-specific transcriptomic atlas and highlights dynamic receptor tyrosine kinase splicing. It identifies ERBB2 i14e and shows its higher expression in cancer, worse prognosis association, and functional support for ERBB3 signaling and AKT activation, with induced expression reducing anti-ERBB2 treatment efficacy and trastuzumab sensitivity improvements upon i14e blockade.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/full-length-transcriptome-atlas-of-gallbladder-cancer-reveals-trastuzumab-resistance-conferred-by-erbb2-alternative-splicing/370263/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/full-length-transcriptome-atlas-of-gallbladder-cancer-reveals-trastuzumab-resistance-conferred-by-erbb2-alternative-splicing/370263.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in gallbladder cancer treatment?","Question",{"text":63,"@type":64},"It focuses on the limited understanding of resistance to ERBB2-targeting therapies in gallbladder cancer and the need for effective targeted strategies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the gallbladder transcriptomic atlas generated?",{"text":68,"@type":64},"The study used advanced long-read full-length transcriptome sequencing across gallbladder normal tissues, tumors, and cell lines.",{"name":70,"@type":61,"acceptedAnswer":71},"What is ERBB2 i14e and how does it contribute to trastuzumab resistance?",{"text":72,"@type":64},"ERBB2 i14e encodes a novel functional protein whose expression is elevated in gallbladder cancer and is associated with worse prognosis; it is spliced from intron 14 and promotes ERBB3 interaction and AKT downstream signaling, reducing trastuzumab efficacy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370263,1790337425,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nFull-length transcriptome atlas of gallbladder cancer revealstrastuzumab resistance conferred by ERBB2 alternative splicing  \nZiyi Wang1,2,3, Li Gao4, Ziheng Jia 1,2,3, Liguo Liu1,2,3, Ao Gu1,2,3, Zhaonan Liu1,2,3, Qin Zhu3, Yichen Zuo4, Mingjie Yang 1,2,3, Shijia Wang5, Jiyao Ma1,2,3, Jingyun Zhang 1,2,3, Shimei Qiu1,2,3, Zhizhen Li6, Jinghan Wang7, Dongxi Xiang2,3, Fatao Liu2,3, Rong Shao3,8,9, Yanjing Li 2,3 ✉ , Maolan Li1,2,3 ✉, Wu Wei 10 ✉ and Yingbin Liu1,2,3,11 ✉  \n|  |  |  |\n| --- | --- | --- |\n|  | Aberrant RNA alternative splicing in cancer generates varied novel isoforms and protein variants that facilitate cancer progression. Here, we employed the advanced long-read full-length transcriptome sequencing on gallbladder normal tissues, tumors, and cell lines to establish a comprehensive full-length gallbladder transcriptomic atlas. It is of note that receptor tyrosine kinases were oneof the most dynamic components with highly variable transcript, with Erb-B2 receptor tyrosine kinase 2 (ERBB2) as a prime representative. A novel transcript, designated ERBB2 i14e, was identiﬁed for encoding a novel functional protein, and its protein expression was elevated in gallbladder cancer and strongly associated with worse prognosis. With the regulation of splicing factors ESRP1/2, ERBB2 i14e was alternatively spliced from intron 14 and the encoded i14e peptide was proved to facilitate the interaction with ERBB3 and downstream signaling activation of AKT. ERBB2 i14e was inducible and its expression attenuated anti-ERBB2 treatment efﬁcacy in tumor xenografts. Further studies with patient derived xenografts models validated that ERBB2 i14e blockage with antisense oligonucleotide enhanced the tumor sensitivity to trastuzumab and its drug conjugates. Overall, this study provides a gallbladder speciﬁc long-read transcriptome proﬁle and discovers a novel mechanism of trastuzumab resistance, thus ultimately |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| devising strategies to improve trastuzumab therapy. |  |  |\n|  | Signal Transduction and Targeted Therapy (2025)10:54 ; [https://doi.org/10.1038/s41392-025-02150-w](https://doi.org/10.1038/s41392-025-02150-w) |  |\n|  |  |  |\n\nINTRODUCTION  \nGallbladder cancer (GBC) is ranked as one of the most malignancies in the digestive system.1,2 The lack of early typical symptoms frequently leads to a delayed diagnosis, resulting in a large population of patients that miss the opportunity for surgery. Consequently, many GBC patients are limited to non-invasive treatment options such as chemotherapy and targeted therapy.3 Unfortunately, the paucity of basic research on GBC has resulted in a dearth of effective targeted therapeutic strategies. Over the past decades, receptor tyrosine kinases (RTKs) have emerged as a predominant membrane factor to deliver oncogenic cues into intracellular signaling activation.4–7 A number of laboratories including ours have demonstrated that ERBB2 possesses the strong ability to drive tumor development in cancers including breast cancer, ovarian cancer, esophageal cancer, gastric cancer and GBC.8,9 Accumulated genomic studies have reported that mutations in the ErbB pathway are genomic hallmarks for GBC, contributing to tumor growth, metastasis, and immune escape.10–13  \nConsequently, ERBB2 merges as the most promising therapeutic target for this poorly understood malignancy.14–17 Trastuzumab, targeting ERBB2, is the ﬁrst monoclonal antibody approved by FDA for cancer therapy. Strikingly, approximate two-thirds of breast cancer patients were tolerant and developed resistance during the treatment.18–20 The unresponsiveness is attributed, at least in part, to the divergent forms of ERBB2 including mutations21 and abnormal dimerization.22,23 To","cbCaisAwssla9xI5","https://ap.wps.com/l/cbCaisAwssla9xI5","pdf",4614619,13,"English","# Introduction\n## Background: gallbladder cancer and ERBB2 targeting\n## Rationale: trastuzumab resistance and the role of alternative splicing\n## Study approach: full-length long-read transcriptome analysis","[{\"question\":\"What problem does the study address in gallbladder cancer treatment?\",\"answer\":\"It focuses on the limited understanding of resistance to ERBB2-targeting therapies in gallbladder cancer and the need for effective targeted strategies.\"},{\"question\":\"How was the gallbladder transcriptomic atlas generated?\",\"answer\":\"The study used advanced long-read full-length transcriptome sequencing across gallbladder normal tissues, tumors, and cell lines.\"},{\"question\":\"What is ERBB2 i14e and how does it contribute to trastuzumab resistance?\",\"answer\":\"ERBB2 i14e encodes a novel functional protein whose expression is elevated in gallbladder cancer and is associated with worse prognosis; it is spliced from intron 14 and promotes ERBB3 interaction and AKT downstream signaling, reducing trastuzumab efficacy.\"}]","Full-length transcriptome atlas of gallbladder cancer reveals trastuzumab resistance conferred by ERBB2 alternative splicing | PDF",1790187673,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/360f34eb0a941b12f3c3426e9a782c38.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16ea10d53407cdc763192f64e9d68cc2.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e9f94f8648328136bee4861f1e10d76.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cf37acf75ebf73006fff7195e3d09d3b.webp",980,1301]